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Abstract
Gene therapy is a promising new therapeutic strategy that has been explored in a wide variety of
diseases, ranging from cancer to hemophilia, and ocular disorders to autoimmune diseases, among
others. Proof of concept of gene transfer approaches has been shown in over 100 studies of animal
models of disease, although only a few are under development for clinical application. The US Food
and Drug Administration and the European Medicines Agency have not approved any viral human
gene therapy products for sale so far, but the amount of gene-related research and development
occurring in the United States and Europe continues to grow at a fast rate. This review summarizes
the current status of developments in the field of viral gene therapy using adeno-associated virus as a
vector, with a special focus on arthritis. For rheumatoid arthritis, and to a lesser extent for other
immune-related inflammatory disorders, several cell and gene transfer approaches have been
investigated at the preclinical level and a few have been implemented in clinical trials. Finally, both the
potential and the hurdles that are faced during development of a viral gene therapy through to its
clinical application are discussed.
Current state and perceived benefits of
adeno-associated virus gene therapy
Gene therapy offers the potential to “cure” inherited
diseases caused by a single error in a single gene in the
human DNA, responsible for a heavy loss of life and
quality of life.Diseases caused by a single error in a single
gene represent approximately 1% of births worldwide
(examples include hemophilia and cystic fibrosis). In
principle, gene therapy in these diseases could introduce
(using a vector) a replacement for the defective gene into
the patient’s cells to restore function. It could also be
used to treat other diseases that arise from a more
complex mix of genetic and/or environmental factors
(such as rheumatoid arthritis, Parkinson’s disease, and
cancer) by introducing a gene encoding a therapeutic
agent into the affected cells or other target cells. Today,
we can envisage a time when we will be able to use gene
therapies in the clinic to treat a spectrum of currently
incurable or virtually untreatable diseases. In practice,
however, introducing the desired gene into the host cells
and getting them to express it in a useful and safe manner
for an extended period of time still poses problems.
Recent advances have now brought us closer to this goal,
and here we outline some of these advances, particularly
in systems for treating nonlethal diseases.
The most efficient types of vector to deliver DNA into a
cell are viruses that have been genetically modified to
carry therapeutic genes. Most of the viral genes are
removed from these viruses to prevent replication of the
virus and to reduce its immunogenicity. Unquestionably,
viruses that infect eukaryotic cells have been the vectors
of choice for gene delivery to mammalian cells. Adeno-
associated virus (AAV) vectors have been identified as
the current most promising gene delivery candidate for
serious nonlethaldiseasesthatneedlong-term treatment.
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that infects humans, and is from the Parvoviridae family.
AAV has a high safety profile (because it does not induce
a large inflammatory response), a lack of toxicity and,
duetothe existence ofdifferentserotypes ofthe virus, can
transduce (transfer into a cell) a wide variety of tissues
and cells in vivo; moreover, long-term expression can
be achieved without integration [1]. In over 60 trials,
AAV-based therapeutic strategies have been tested in
humans, some of which have shown very promising
results at immunoprivileged sites. Several clinical trials
have shown success in terms of initial safety and proof
of concept. To date, one AAV-based therapeutic vector
has been submitted to the European Medicines Agency
(EMA) for evaluation. However, these clinical trials have
also identified problems associated with vector admin-
istration in humans that were not seen during the
preclinical studies in rodents and were not even seen in
nonhuman primates. This includes the presence of
pre-existing neutralizing antibodies to the AAV vector,
loss of transgene expression over time, and (too) low
expression of the transgene. In addition, certain studies,
like a Phase IIB trial in patients with cystic fibrosis,
showed that the AAV vector was well tolerated and safe,
but no significant improvement in lung function could
be observed, probably due to low transduction efficiency
of the AAV vector. Consequently, research to overcome
these barriers to the development of safe and effective
gene therapy in various disease areas is ongoing.
Clinical trials using AAV as vector for different
diseases
Clinical studies for the treatment of alpha1-antitrypsin
deficiency, Alzheimer’s disease, arthritis, Batten’s disease,
Canavan’s disease, cystic fibrosis, hemophilia B, HIV
infection, Leber’s congenital amaurosis, lipoprotein
lipase (LPL) deficiency, Parkinson’s disease, muscular
dystrophy, and malignant melanoma have been initiated
(see Gene Therapy Clinical Trials Worldwide, provided
by the Journal of Gene Medicine [2]). A few of these trials
demonstrating the recent advances and hurdles in the
field of AAV clinical gene therapy will be highlighted
below.
Leber’s congenital amaurosis
The first clear demonstration of long-term efficacy
following administration of a transgene with an AAV
vector in humans was demonstrated in two independent
Phase I AAV clinical trials in ophthalmological disease.
The eye is an easily accessible, highly compartmentalized
and immune-privileged organ offering unique advan-
tages for local gene therapy. The objective was to treat
blindness in patients affected by Leber’s congenital
amaurosis, an autosomal recessive disease leading to
blindness. Both trials used the AAV2 serotype vector.
One was performed in London, UK, and the other in
Philadelphia, USA. The main differences between the
trials were the use of a constitutive promoter to drive
transgene expression in the US trial [3], compared with
the use of elements of the endogenous (host) RPE65
(retinal pigment epithelium-specific 65 kDa protein)
promoter in the UK trial [4]. Moreover, the patients
treated in the UK were all adolescent; no children with
less progressive disease were treated. In both studies,
only subjects in whom the disease was caused by a
deficiency in human RPE65, responsible for blindness in
approximately 10% of the patients with Leber’s con-
genital amaurosis, were included.
The first trial was performed in the United States; a single
eye was treated in each of 12 pediatric and adult subjects
(8–44 years) by a subretinal injection of an AAV2 vector
containingtheRPE65geneinoneofthreedoses(1.5×10
10
vector genomes [vg], 4.8×10
10 vg, and 1.5×10
11 vg) This
trial showed an excellent safety profile and objective
evidence of long-term efficacy [5]. AAV2-hRPE65v2 was
well tolerated and all patients showed sustained improve-
ment in subjective and objective measurements of vision.
The greatest improvement was noted in children. No
neutralizing antibody levels were detectable after the
first injection. Since patients who had one eye treated
experienced such an improvement in vision, they
requested treatment of their second eye. Results of
injectionofthe secondeye inpatientspreviously receiving
the gene therapeutic vector are awaited and are important,
as they will show whether redosing with the same AAV
serotype in an immune-privileged site is feasible without
inducing an immune response against the vector. In the
secondtrial,performed in the UK,three patientsin the age
range of 17 to 23 years were treated. All patients received
doses of 1×10
11vector particles. Visualfunctionimproved
in only one patient; the other two probably had more
advanced retinal disease at baseline, which may explain
why they did not exhibit clinical improvement. Whether
further retinal degeneration is delayed in any of the
patients will become apparent only after several years.
The comparison between the effect of a constitutive AAV
promoter versus a host tissue-specific promoter in terms
of safety and efficacy will be of particular interest. Even
though only a small percentage of patients will directly
benefit from this particular treatment, the general techni-
que of AAV-mediated transfer of a transgene into retinal
cells has been shown to work well, and will likely be used
in other forms of retinal blinding disorder in the near
future. Overall, different treatment strategies based on
AAV-mediatedgenetherapyapproachesareinthepipeline
for retinal blinding disorders and may soon advance to
the clinic [6].
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Hemophilia B is an attractive target disease for gene
therapy, as stable expression of coagulation factor IX may
correct the bleeding diathesis. Initial clinical trials for
hemophilia, using different vectors, showed that gene
therapy was safe but did not demonstrate any therapeu-
tic effect. In 1999, a Phase I/II clinical trial was initiated
to test the safety and efficacy of intramuscularly delivered
AAV vectors encoding a cytomegalovirus-driven factor IX
transgene [7]. No toxicity was observed over 7 years of
follow-up after vector administration. Muscle biopsies
taken 2 months, 10 months, and >3 years after vector
administration revealed the persistence of vector gen-
omes as well as local expression of the factor IX protein.
However, these levels of factor IX were not therapeuti-
cally effective. In this study, the barrier to the use of this
approach as a treatment was the number of muscle
injections required to reach a therapeutic effect in an
adult hemophilia B patient.
Next, a second clinical trial testing the safety and efficacy
of an AAV vector was initiated [8]. In this trial, a liver-
specific promoter was used to drive expression of the
factor IX transgene. The vector was infused into the
hepatic artery of hemophilia B subjects at three different
doses. Only one patient treated with the highest dose
(2×10
12 vg/kg) showed expression of the transgene
2 weeks after vector infusion; however, thereafter levels
slowly declined to reach baseline after a further 8 weeks.
This decrease was accompanied by an increase in liver
transaminase levels, which indicates transaminitis
(reflecting liver cell damage). It was demonstrated that
the loss of transgene expression was caused by a T-cell-
mediated response to the vector capsid resulting in
elimination of the transduced hepatocytes [9]. Impor-
tantly, the T-cells’ activation and transaminase response
appeared to be vector-dose dependent and was not
seen in patients treated with a lower vector dose. This
phenomenon had not been observed in any animal
model after AAV transduction, but unlike most labora-
tory animals, humans are frequently exposed to wildtype
AAV viruses in the context of pathogens from very early
childhood. These exposures, because they occur in the
context of helper viruses such as adenovirus, which evoke
a strong immune response, may also evoke an immune
response to AAV vector proteins that could be reactivated
by the AAV vector.
There are possible ways to counter this immunogenicity:
conceivably, transient immunosuppression may poten-
tially overcome T-cell-mediated immune responses;
alternatively, vectors could be developed that result in
higher factor IX expression levels at much lower vector
doses. Indeed, the latter strategy has been investigated in
nonhuman primates [10]. A self-complementary AAV
(scAAV) vector was generated, containing double-
stranded DNA instead of single-stranded DNA and
therefore not requiring double-strand synthesis after
transduction into the cell. This resulted in a higher
transgene expression with lower doses of vector. In
addition, the transgene was packaged in an AAV serotype
8 capsid, which has an advantage over the AAV2 vector
regarding the reduced presence of pre-existing antibodies
to the vector in humans, and results in reduced uptake by
antigen-presenting cells compared to AAV2 (due to the
tropism of AAV8). Based on the preclinical data, a GMP
(Good Manufacturing Practice) batch was produced [11]
and a Phase I/II clinical trial has recently been initiated in
patients with hemophilia B. In another trial in Philadel-
phia, the former approach of concomitant immune
suppression is currently under investigation.
Lipoprotein lipase deficiency
LPL deficiency is an autosomal recessive disease asso-
ciated with severe hypertriglyceridemia, severe chylomi-
cronemia, and low levels of high-density lipoprotein,
which can lead to acute pancreatitis. Currently, no drug
therapy is available but gene therapy with LPL could be a
good option for these patients. An AAV1 vector, expres-
sing the human LPL variant LPL
S447X, was generated and
tested in a Phase I/II, open-label (i.e., not blinded) dose-
escalation clinical trial and followed by a Phase II/III
study [12]. AAV1.LPL
S447X (AMT-011, alipogene tiparvo-
vec, Glybera) was administrated by a single series of
intramuscular injections in multiple sites of the limbs
(range from 30–70 injections, depending upon body
weight). In the first study, the gene therapy vector was
well tolerated at a dose of 3×10
11 vg/kg. No data about
expression levels are available but, in two of the four
subjects treated with the highest dose, a >40% reduction
in triglyceride levels was observed, which could
obviously not be compared to controls. T cell immune
responses against AAV1 capsid were detected in half of
the subjects in the first month after administration of the
drug [13]. In the second study (performed in Quebec,
Canada), 14 patients were included. This study was a
dose-escalation study with two patients receiving a dose
of 3×10
11 vg/kg, four patients receiving the same dose as
the first group but in combination with immuno-
suppressive medication to avoid the T-cell responses,
and eight in the highest dose group (1×10
12 vg/kg) in
combination with immunosuppressants. Immunosup-
pressive treatment consisted of cyclosporine (3 mg/kg)
andmycophenolatemofetil(2g/day)fromday3until12
weeks after study drug administration. In a third study,
the protocol was modified to includean additional bolus
injection of the anti-inflammatory drug methylpredni-
solon prior to the vector. As five patients with a previous
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study, it will be interesting to see the incidence of
pancreatitisinLPLfollowingAAV1.LPL
S447Xgenetherapy
over the coming years. In summary, AAV1.LPL
S447X was
tolerated well, without dose-limiting toxicity; also, in
long-term follow-up, this therapy has produced an
excellent safety profile so far [14]. During the active
study phase, a decrease in triglyceride levels was noted in
virtually all patients. Muscle biopsies taken half a year
later in the second group from both injected and
noninjected muscle clearly indicated persistent expres-
sion and biologic activity. Alipogene tiparvovec is now
under review at the EMA as a new therapeutic agent for
LPL deficiency. If the submission is approved by the EMA
in the next year, then alipogene tiparvovec might be the
first (AAV) gene therapy compound on the market in
Europe.
Rheumatoid arthritis
Rheumatoid arthritis is a progressive destructive disorder
primarily targeting the joints. Advances in the under-
standing of the pathophysiology of rheumatoid arthritis
have allowed important and innovative approaches to its
treatment. During the last decade, development of
therapies targeting tumor necrosis factor (TNF) and
other new drugs, together with an improved timing and
dosing of conventional therapy, has largely improved the
outcome of established arthritis in many patients, but
cannot induce a complete remission in all. Most of the
patients still have some level of synovial inflammation
in one or more joints. Another major problem of current
systemic treatment is the need for ongoing therapy.
Gene therapy could theoretically offer long-term treat-
ment, resulting in sustained remission without the need
for frequent repeated treatments. Although various
proof-of-concept strategies have been demonstrated in
preclinical models, those aimed at direct in vivo gene
delivery to the synovial tissue in the joints are closest to
clinical application.
Gene therapy studies using AAV in animal models of rheumatoid
arthritis
Since it has been shown that TNF plays a key role in the
initiation and perpetuation of synovial inflammation,
and biologicals targeting TNF are successful in treating
rheumatoidarthritisinbothanimalmodelsandpatients,
several gene therapeutic approaches aimed at blocking
TNF activity have been tested in the past few years. In one
of the studies using streptococcal cell wall-induced
arthritis in rats [15], intra-articular administration of a
recombinant AAV2 vector containing cDNA encoding a
rat p75 TNF receptor-2 (TNFR2):Fc fusion gene sup-
pressed arthritis. This study formed the basis for a clinical
trial in which a recombinant AAV2 vector expressing the
human TNFR2:Fc protein, a protein identical to the anti-
TNF drug etanercept, was tested in patients with
inflammatory disease (see Clinical trials in rheumatoid
arthritis section, below).
Most of the preclinical and clinical data for rheumatoid
arthritis have been generated using AAV serotype 2 as a
vector. However, in 2005, two independent studies
compared serotypes 1 to 5, and showed that recombinant
AAV serotype 5 was the most efficient recombinant
AAVvectorfortransducingsynovialtissueinvivo,fo ll ow ed
by recombinant AAV2 [16,17]. Subsequently, the transdu-
cing efficiency of recombinant AAVs was demonstrated in
inflamed joints of horses [18]. In addition to its superior
transduction efficiency, AAV5 has the important advan-
tage that neutralizing antibodies against AAV5 are rare
in the human population compared with AAV2 [19]. We
havedemonstratedthatthis alsoholdstruein rheumatoid
arthritis patients (unpublished results). Both preclinical
and clinical studies showed that antibodies against the
AAVcapsidmayblocktransductionatverylowtiterswhen
the vector is introduced into the bloodstream [20], even
when it is close to the target tissue, whereas gene transfer
inimmune-privilegedbodycompartments,suchastheeye
and the brain, seems to be less susceptible to neutraliza-
tion. In another step forward, recombinant AAV5 gene
constructs expressing a TNF-blocking agent, a chimeric
human TNF soluble receptor-1 linked to a mouse
immunoglobulin heavy chain Fc portion (TNFR1:Fc),
reducedarthritisscore,pawswelling,andjointdestruction
in two animal models of arthritis [21,22].
Another approach, which has been investigated by
several groups, is the overexpression of anti-inflamma-
tory cytokines locally in the joint. Our own group
explored inducing overexpression of interferon-beta
(IFNb) in inflamed joints. After successful treatment of
arthritis with IFNb protein in animal models, we showed
that intra-articular IFNb gene therapy using recombinant
AAV5-expressing rat IFNb resulted in reduced paw
swelling and synovial inflammation in rat adjuvant
arthritis [23]. In addition, IFNb treatment protected
against bone and cartilage destruction. Similarly, toxicity
and biodistribution studies have been initiated, evaluat-
ing the effects of a clinical recombinant AAV5 vector
expressing human IFNb (ART-I02) in collagen-induced
arthritis in rhesus monkeys. Preliminary results indicated
that local treatment with high doses of ART-I02 is not
toxic and is well tolerated in the animals, but also
revealed the production of neutralizing antibodies to the
vector after local injection in the joint. Although this
does not interfere with the transduction of cells in vivo
after the first administration of the vector, it can
Page 4 of 8
(page number not for citation purposes)
F1000 Medicine Reports 2011, 3:17 http://f1000.com/reports/m/3/17potentially have an effect on repeated administration of
the vector if a second injection is needed. The next step
will be the performance of pharmacology and toxicology
studies under GLP (Good Laboratory Practice) condi-
tions before conducting a Phase I clinical trial in
rheumatoid arthritis patients.
Clinical trials in rheumatoid arthritis
To date, only a few clinical gene therapy trials have been
performed in rheumatologic diseases, with four
trials targeting proinflammatory cytokines for the treat-
ment of rheumatoid arthritis. The first gene therapy trial
in rheumatoid arthritis patients investigated safety and
feasibility of ex vivo gene therapy [24]. Autologous
fibroblast-like synoviocytes were transduced with a retro-
viral vector expressing interleukin-1 receptor antagonist
(IL-1RA). After 1 week, injected joints were removed and
examined for evidence of successful gene transfer. In joints
treated with transduced cells, mRNA transgene expression
w a ss h o w n ,a sw e l la sc l u s t e r so fc e l l se x p r e s s i n gh i g h
levels of IL-1RA. No adverse events were recorded. Despite
these promising results, this ex vivo gene therapy approach
was not further developed for clinical application because
of the expense and time involved.
More recently, Targeted Genetics Corporation performed
two clinical trials in rheumatoid arthritis patients using
an in vivo gene therapy approach with recombinant
AAV2 [25,26]. The Phase I study investigated the safety
of an intra-articular injection of a recombinant AAV2
vector coding for a TNF receptor IgG1 fusion gene
(tgAAC94). Doses up to 1×10
11 particles per milliliter of
jointvolumewerewelltolerated.Subsequently,ina Phase
I/II study, the clinical response to administration of
tgAAC94 was investigated in 127 patients with inflam-
matory arthritis (including rheumatoid and psoriatic
arthritis, and those with other arthritides). Patients
received a single intra-articular injection of tgAAC94 (at
three different dosages: 1×10
11,1 × 1 0
12,o r1 × 1 0
13
particles per milliliter of joint volume) or placebo. This
treatment was followed by an open-label injection
after 12–30 weeks. No change in arthritis score was
observed upon physical examination, but patient-
reported outcomes did show a nonsignificant trend
towards a response. Common adverse reactions were
injection site reactions, but otherwise the treatment was
well tolerated. The study encountered one serious adverse
event: one patient, who was on concurrent systemic anti-
TNF antibody treatment, developed fatal disseminated
histoplasmosis, a fungal infection, which was ultimately
considered unrelated to the study agent [27].
These trials provided encouraging data on safety and
feasibility for further development of gene therapy for
rheumatoid arthritis. Future clinical trials will need to
address whether long-term expression of a therapeutic
gene and therapeutic efficacy can be obtained using other
recombinant AAV vectors. It will also be important to
exclude patients with significant pre-existing neutralizing
antibody titers to the recombinant AAV serotype used.
The information generated in these trials will be critical
to further develop local gene therapy for rheumatoid
arthritis patients.
Hurdles and possible solutions for developing
AAV gene therapy for clinical application
As already briefly discussed above, one major problem is
the development of immune responses against the vector
or against the transgene, resulting in low and/or short-
term transgene expression. The type of immune response
depends on a variety of factors, such as the route of
application, the target tissue, the vector serotype and
dose, the disease targeted, and the expression level of the
transgene.
Several strategies have been explored to minimize
immune responses against the vector. Since the immune
responses are dose dependent, one approach is to
optimize the expression cassettes, resulting in higher
expression levels using lower doses of vector. Currently,
the most widely used promising techniques, at least at the
preclinical level, are the use of self-complementary vectors
[9] and/or codon-optimized sequences for the expression
of transgenes [28]. Such modified gene constructs are
being tested in ongoing clinical trials, which should show
if these changes translate into clinical benefits.
In many preclinical studies and clinical trials, neutraliz-
ing antibodies to AAV were generated after the first
injection. Although, ideally, gene therapy should pro-
duce lifelong treatment after a single injection, it appears
more likely that repeated injections will be needed. One
strategy to avoid the negative effect of neutralizing
antibodies to the vector after the second injection would
be to switch to a different vector serotype. Alternatively,
the development of an immune response to the vector
might be inhibited by immunosuppressive drugs.
Finally, AAV capsid mutants could be designed to escape
the induction of immune responses by avoiding uptake
of the vector by antigen presenting cells. This last
approach may also be advantageous in patients who
have pre-existing neutralizing antibodies to AAV due to
previous AAV infection [29].
Immune responses to the transgene product mostly
occur in diseases where gene therapy is used to replace a
“missing” gene and when the transgene is relatively large.
Several investigators have demonstrated induction of
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ing gene transfer to hepatocytes [30]. Future studies will
be needed to explore the induction of tolerance more
precisely in different diseases in which an immune
response to the transgene is a problem.
Besides the development of immune responses, there are
many other hurdles that need to be overcome. Many of
these are disease-, transgene-, or target tissue-specific
problems and all need specific solutions to be resolved.
For example, the sizes of some therapeutic genes exceed
the packaging limit (~5 kb) of an AAV vector. Conse-
quently, the design of truncated versions of the
transgene, or the development of two vectors expressing
fragments of the transgene, is under investigation.
Another challenge may be limited transduction of the
target tissue. In addition to escaping the immune
response, AAV capsid mutants can improve the transduc-
tion efficacy and specific targeting of tissues and cells that
are difficult to transduce [31] such as is the case in cystic
fibrosis.
One problem that is unlikely to occur with AAV is the
safety issues that arise when vectors integrate into the
host genome. However, integration is a safety issue with
theuseofsomevectors,suchasretroviruses.Forexample,
in a trial for X-linked severe combined immunodefi-
ciency, insertional mutagenesis in the host genome at an
oncogenic site led to the development of leukemia in
5 out of more than 20 treated patients [32]. In contrast,
no malignancy caused by vectors used in clinical gene
therapy trials have been reported in trials predominantly
using nonintegrating vectors, such as recombinant AAV
(AAV achieves long-term expression by the formation of
stable concatemers, but does not generally integrate into
the host genome). However, recombinant AAV vectors
have shown a very low frequency of integration in the
host genome in preclinical studies in mice, but the risk of
insertional mutagenesis seems very low [33]. However,
future Phase II and III trials have to elucidate if, and how
frequently, insertion will occur when large groups of
patients are treated with recombinant AAV vectors.
Furthermore, problems concerning the manufacturing of
clinical-grade recombinant AAV batches need to be
solved. Currently, sufficient GMP-certified labs, which
are required to produce the vectors for the European
market, are lacking. Standardized methods for batch
release, including determining the titer of the batches,are
warranted in order to be able to compare the results
obtained in studies performed by different labs. It
remains to be seen whether it will be possible to
overcome the hurdles discussed above.
The next phase in AAV gene therapy trials
BringingAAV genetherapytotheclinic isexpectedtobea
relatively long process. However, in the past few years the
resultsgeneratedinPhaseI/IIclinicaltrialsrepresentabig
step forward for AAV-based gene therapy as treatment for
nonlethal diseases. Although clinical trials such as the
hemophilia B trial have shown that not all results can be
predicted when based on (large) animal models, the
Leber’s congenital amaurosis trials have shown the safety
and (at least partial) efficacy over a longer period after a
single injection of an AAV vector. The submission of the
first AAV gene therapy product to the EMA is a fact.
Also, AAV gene therapy has shown a good safety profile
over a long period of time (follow-up of more than 7
years in patients). Future studies will need to show
whether results of AAV gene therapy currently in late-
phase clinical development are convincing enough to
allow these products onto the market.
New advances in the development of AAV gene therapy
towards the clinic include the use of alternative serotypes
such as recombinant AAV5 for rheumatoid arthritis and
recombinant AAV8 for the treatment of hemophilia, or
AAV capsid mutants. Different kinetics of uncoating as
well as differences in intracellular trafficking and antigen
processing may lead to differences in capsid processing
and presentation of alternate serotypes. In combination
with next generation vectors carrying self-complemen-
tary and codon-optimized transgenes, which enhance
transgene expression at lower doses, this could perhaps
also overcome the problem of pre-existing and newly
formed neutralizing antibodies to AAV as well as T-cell-
mediated immune responses. Furthermore, more data
are needed to show if the use of immunosuppressive
agents may be sufficiently effective to avoid cell-
mediated immune-responses.
Overall, gene therapy has enormous potential for treating
disease and ways will be found around many of the
technical obstacles. It remains to be seen whether we can
overcome all of them and fulfill the promise of this
approach.
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